Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | suspended | Phase 1 / Phase 2 | 65 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT03181035 | Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer(FAITH) | suspended | Phase 1 / Phase 2 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 12, 2024 |
| clinicaltrials |
| NCT04120246 | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | suspended | Phase 1 | 24 | Veana TherapeuticsINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT05643690 | Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay | suspended | — | 77 | AnchorDx Medical Co. Ltd. USINDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04619186 | Diffusion-Weighted MRI for Breast Cancer Screening in Women With a Personal History of Breast Cancer | suspended | — | 1,694 | Seoul National University HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT04090463 | IORT on Borderline Resectable Pancreatic Cancer(PancFORT) | suspended | Phase 2 | 100 | Universita di VeronaOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT04684628 | 68Ga-PSMA PET/CT in Prostate Cancer | suspended | Phase 3 | 500 | University of SaskatchewanOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | suspended | Phase 1 | 30 | DNAtrix, Inc.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06355843 | Clinical Applications of Integrated PET/MR and PET/CT in the Diagnosis and Treatment of Prostate Cancer. | suspended | N/A | 50 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT02546102 | Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma | suspended | Phase 3 | 234 | Precision Life Sciences GroupINDUSTRY | 3 | Apr 3, 2024 | clinicaltrials |
| NCT03932253 | MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) | suspended | Phase 1 | 79 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT04668768 | HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma | suspended | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Mar 22, 2024 | clinicaltrials |
| NCT05361915 | Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | suspended | Phase 2 | 100 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Mar 18, 2024 | clinicaltrials |
| NCT05101616 | A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer | suspended | Phase 1 / Phase 2 | 100 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02579005 | Radio-Immuno-Modulation in Lung Cancer(RIM) | suspended | Phase 1 | 24 | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de MontrealOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05168904 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 210 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05233007 | Upper GI Serial Tumour Biopsies | suspended | — | 300 | The Christie NHS Foundation TrustOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05756556 | T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma | suspended | Phase 2 | 68 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | suspended | Phase 1 | 16 | Syros PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 9 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04558684 | Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer | suspended | Phase 1 / Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT02146508 | Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital(EXPECT) | suspended | N/A | 75 | Tenwek HospitalOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer(REPAIR) | suspended | Phase 1 | 48 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | suspended | Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05421936 | Osimertinib for NSCLC With Uncommon EGFR Mutations(UNICORN) | suspended | — | 100 | Sheba Medical CenterOTHER_GOV | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | suspended | Phase 1 / Phase 2 | 40 | Myeloid TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04125524 | Terahertz Metamaterials for Tumour Marker Concentration Identification | suspended | — | 90 | Durham UniversityOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT03659669 | A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice(REVEAL) | suspended | — | 272 | AbbVieINDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04485052 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia | suspended | Phase 1 / Phase 2 | 222 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04427306 | Neoadjuvant T-VEC in High Risk Early Melanoma | suspended | Phase 2 | 6 | University of California, DavisOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03229876 | Safety and Efficacy Evaluation of CD19-UCART | suspended | N/A | 20 | Bioray LaboratoriesINDUSTRY | 1 | Jul 24, 2023 | clinicaltrials |
| NCT03218475 | MRG FU With Radiotherapy for Palliation of H&N Cancer | suspended | N/A | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03055208 | Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma(Gamma-GBM) | suspended | N/A | 50 | Universitätsmedizin MannheimOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT03002103 | A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer | suspended | Phase 3 | 420 | SynCore Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 26, 2023 | clinicaltrials |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors | suspended | Phase 1 | 220 | Bellicum PharmaceuticalsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05158907 | Patient Reported Scale vs CTCAE Grading: A Prospective Comparator Study(PROSE) | suspended | N/A | 220 | Tata Medical CenterOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT02262221 | Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer(HETeCo) | suspended | N/A | 330 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 2 | Mar 13, 2023 | clinicaltrials |
| NCT05506800 | Guangzhou Women's Health Cohort Study (GWHCS) | suspended | — | 1,000,000 | Guangzhou Women and Children's Medical CenterOTHER | 1 | Feb 23, 2023 | clinicaltrials |
| NCT01933815 | Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma | suspended | Phase 1 / Phase 2 | 92 | Cortice Biosciences, Inc.INDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | suspended | Phase 1 / Phase 2 | 227 | Clovis Oncology, Inc.INDUSTRY | 6 | Dec 20, 2022 | clinicaltrials |
| NCT04746131 | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) | suspended | Phase 1 | 90 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT05089461 | A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor | suspended | Phase 2 | 120 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | suspended | Phase 1 / Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT03322813 | ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma | suspended | N/A | 15 | InSightecINDUSTRY | 1 | Aug 3, 2022 | clinicaltrials |
| NCT04116281 | Short and Long Term Effects of a Physical Therapy Program After Breast Cancer Surgery | suspended | N/A | 36 | Universidade Federal de Sao CarlosOTHER | 1 | Jul 12, 2022 | clinicaltrials |
| NCT01982175 | Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia(CLL004) | suspended | Phase 2 | 120 | Shanghai Zhangjiang Biotechnology Limited CompanyINDUSTRY | 1 | Jun 21, 2022 | clinicaltrials |
| NCT03752541 | Efficacy and Safety Evaluation of BCMA-UCART | suspended | N/A | 20 | Bioray LaboratoriesINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT02897050 | Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer | suspended | Phase 2 | 170 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT04219475 | Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients(PROPHETIC) | suspended | — | 1,000 | OncoHost Ltd.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | suspended | Phase 1 | 12 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 19, 2024source: clinicaltrials